Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 5Completed 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Cyclophosphamide 21fludarabine 17Specimen Handling 13Magnetic Resonance Spectroscopy 10pembrolizumab 9Nivolumab 9Radiotherapy 7Cisplatin 7fludarabine phosphate 5Injections 5tislelizumab 4daratumumab 4Rituximab 4Paclitaxel 4Ipilimumab 4Interleukin-2 4Immune Checkpoint Inhibitors 4Gemcitabine 4Fluorouracil 4Drug Therapy 4Doxorubicin 4Dexamethasone 4Carboplatin 4Biopsy 4venetoclax 3toripalimab 3X-Rays 3Radiosurgery 3Platinum 3Oxaliplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Not yet recruiting × revumenib × Clear all
NCT07283640 2026-05-05

A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 1 Not yet recruiting
20 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡